Polymer therapy: A novel treatment to improve fat graft viability

Plastic and Reconstructive Surgery

Volumn 127, Issue 6, 2011, Pages 2270-2282

  Medina III, Miguel A ^a   Nguyen, John T ^a   Kirkham, John C ^a   Lee, Jeffery H ^a   McCormack, Michael C ^a   Randolph, Mark A ^a   Austen, William G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; POLOXAMER;

ADIPOSE TISSUE; ANIMAL; APOPTOSIS; ARTICLE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ELECTRON MICROSCOPY; GRAFT SURVIVAL; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TRANSPLANTATION;

ADIPOSE TISSUE; ANIMALS; APOPTOSIS; CELL SURVIVAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT SURVIVAL; HUMANS; MICE; MICE, NUDE; MICROSCOPY, ELECTRON; POLOXAMER;

EID: 79958715262     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3182139fc1     Document Type: Article

References (39)

1. Coleman SR. Structural fat grafts: The ideal filler? Clin Plast Surg. 2001;28:111-119. (Pubitemid 32171582)
2. Giugliano C, Benitez S, Wisnia P, Sorolla JP, Acosta S, Andrades P. Liposuction and lipoinjection treatment for congenital and acquired lipodystrophies in children. Plast Reconstr Surg. 2009;124:134-143.
3. Gutowski KA; ASPS Fat Graft Task Force. Current applications and safety of autologous fat grafts: A report of the ASPS fat graft task force. Plast Reconstr Surg. 2009;124:272-280.
4. Boschert MT, Beckert BW, Puckett CL, Concannon MJ. Analysis of lipocyte viability after liposuction. Plast Reconstr Surg. 2002;109:761-765; discussion 766-767. (Pubitemid 34118454)
5. Hyakusoku H, Ogawa R, Ono S, Ishii N, Hirakawa K. Complications after autologous fat injection to the breast. Plast Reconstr Surg. 2009;123:360-370; discussion 371-372.
6. Lam SM, Glasgold RA, Glasgold MJ. Limitations, complications, and long-term sequelae of fat transfer. Facial Plast Surg Clin North Am. 2008;16:391-399, v.
7. Yamaguchi M, Matsumoto F, Bujo H, et al. Revascularization determines volume retention and gene expression by fat grafts in mice. Exp Biol Med (Maywood) 2005;230:742-748. (Pubitemid 41565943)
8. Gonzalez AM, Lobocki C, Kelly CP, Jackson IP. An alternative method for harvest and processing fat grafts: An in vitro study of cell viability and survival. Plast Reconstr Surg. 2007;120:285-294. (Pubitemid 46956065)
9. Medina MA III, Nguyen JT, McCormack MM, Randolph MA, Austen WG Jr. A high-throughput model for fat graft assessment. Lasers Surg Med. 2009;41:738-744.
10. Greenebaum B, Hannig J, Carrillo CS, et al. Poloxamer 188 prevents acute necrosis of adult skeletal muscle cells following high-dose irradiation. Burns 2004;30:539-547. (Pubitemid 39092346)
11. Lee RC, River LP, Pan FS, Ji L, Wollmann RL. Surfactantinduced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad Sci USA. 1992;89:4524-4528.
12. Maskarinec SA, Wu G, Lee KY. Membrane sealing by polymers. Ann N Y Acad Sci. 2005;1066:310-320.
13. Khattak SF, Bhatia SR, Roberts SC. Pluronic F127 as a cell encapsulation material: Utilization of membrane-stabilizing agents. Tissue Eng. 2005;11:974-983. (Pubitemid 40960799)
14. Ramon Y, Shoshani O, Peled IJ, et al. Enhancing the take of injected adipose tissue by a simple method for concentrating fat cells. Plast Reconstr Surg. 2005;115:197-201; discussion 202-203. (Pubitemid 40187814)
15. Yi C, Pan Y, Zhen Y, et al. Enhancement of viability of fat grafts in nude mice by endothelial progenitor cells. Dermatol Surg. 2006;32:1437-1443. (Pubitemid 44934891)
16. Murphy AD, McCormack MC, Bichara DA, et al. Poloxamer 188 protects against ischemia-reperfusion injury in a murine hind-limb model. Plast Reconstr Surg. 2010;125:1651-1660.
17. Schaer GL, Hursey TL, Abrahams SL, et al. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function. Circulation 1994;90: 2964-2975.
18. Schaer GL, Spaccavento LJ, Browne KF, et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction: Results of a randomized, double-blind, placebo-controlled trial. Circulation 1996;94:298-307. (Pubitemid 26266112)
19. Watanabe M, Okada T. Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart. Mol Cell Biochem. 2003;248: 209-215. (Pubitemid 36840813)
20. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005;436:1025-1029. (Pubitemid 41191686)
21. Birchenough SA, Rodeheaver GT, Morgan RF, Peirce SM, Katz AJ. Topical poloxamer-188 improves blood flow following thermal injury in rat mesenteric microvasculature. Ann Plast Surg. 2008;60:584-588. (Pubitemid 351591470)
22. Hannig J, Zhang D, Canaday DJ, et al. Surfactant sealing of membranes permeabilized by ionizing radiation. Radiat Res. 2000;154:171-177. (Pubitemid 30612917)
23. Merchant FA, Holmes WH, Capelli-Schellpfeffer M, Lee RC, Toner M. Poloxamer 188 enhances functional recovery of lethally heat-shocked fibroblasts. J Surg Res. 1998;140:131-140. (Pubitemid 28270361)
24. Pu LL, Cui X, Fink BF, Cibull ML, Gao D. The viability of fatty tissues within adipose aspirates after conventional liposuction. Ann Plast Surg. 2005;54:288-292; discussion 292. (Pubitemid 40279479)
25. Serbest G, Horwitz J, Barbee K. The effect of poloxamer-188 on neuronal cell recovery from mechanical injury. J Neurotrauma 2005;22:119-132.
26. Marks JD, Pan CY, Bushell T, Cromie W, Lee RC. Amphiphilic, tri-block copolymers provide potent membrane-targeted neuroprotection. FASEB J. 2001;15:1107-1109.
27. Borgens RB, Bohnert D, Duerstock B, Spomar D, Lee RC. Subcutaneous tri-block copolymer produces recovery from spinal cord injury. J Neurosci Res. 2004;76:141-154. (Pubitemid 38445572)
28. Quinn M, Mukhida K, Sadi D, Hong M, Mendez I. Adjunctive use of the non-ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease. Eur J Neurosci. 2008;27:43-52.
29. Zhang Z, al-Rubeai M, Thomas CR. Effect of Pluronic F-68 on the mechanical properties of mammalian cells. Enzyme Microb Technol. 1992;14:980-983.
30. Tharmalingam T, Ghebeh H, Wuerz T, Butler M. Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol Biotechnol. 2008;39:167-177.
31. Kurita M, Matsumoto D, Shigeura T, et al. Influences of centrifugation on cells and tissues in liposuction aspirates: Optimized centrifugation for lipotransfer and cell isolation. Plast Reconstr Surg. 2008;121:1033-1041; discussion 1042-1043. (Pubitemid 351642841)
32. Ferguson RE, Cui X, Fink BF, Vasconez HC, Pu LL. The viability of autologous fat grafts harvested with the LipiVage system. Ann Plast Surg. 2008;60:594-597. (Pubitemid 351591472)
33. Rohrich RJ, Sorokin ES, Brown SA. In search of improved fat transfer viability: A quantitative analysis of the role of centrifugation and harvest site. Plast Reconstr Surg. 2004;113:391- 395; discussion 396-397. (Pubitemid 39202061)
34. Suga H, Matsumoto D, Inoue K, et al. Numerical measurement of viable and nonviable adipocytes and other cellular components in aspirated fat tissue. Plast Reconstr Surg. 2008; 122:103-114.
35. Lee RC, Despa F, Tang X, et al. Direct observation of the p188 mediated membrane sealing with atomic force microscopy. Mol Cell Biomech. 2006;3:185-186. (Pubitemid 46139162)
36. Maskarinec SA, Hannig J, Lee RC, Lee KY. Direct observation of poloxamer 188 insertion into lipid monolayers. Biophys J. 2002;82:1453-1459. (Pubitemid 34204765)
37. Wu G, Lee KY. Effects of poloxamer 188 on phospholipid monolayer morphology: An atomic force microscopy study. Langmuir 2009;25:2133-2139.
38. Agarwal J, Walsh A, Lee RC. Multimodal strategies for resuscitating injured cells. Ann N Y Acad Sci. 2005;1066: 295-309.
39. Singh-Joy SD, McLain VC. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol. 2008;27(Suppl 2):93-128.